David Venables joins Ark board
This article was originally published in Scrip
Dr David Venables has joined Ark Therapeutics' board as executive director for manufacturing services. He will be responsible for building Ark's manufacturing services business which is key to the company's future development. Dr Venables joins from Intercell where he was responsible for building its manufacturing capabilities in Europe and the US, most recently as chief operating officer.
You may also be interested in...
Orchard Therapeutics is on the cusp of the first approval for its ex vivo gene therapy, Libmeldy, for metachromatic leukodystrophy.
Gilead/Kite’s second CAR-T product is given the go-ahead for approval by the CHMP for mantle cell lymphoma.
A Phase III trial of Swedish Orphan Biovitrum’s Doptelet in solid tumor cancer patients with chemotherapy-induced thrombocytopenia has failed. The setback could affect the firm’s growth expectations.